KAN.ST Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (31 May 2024 @ 11:29):

Stats
Today's Volume	500 671
Average Volume	444 784
Market Cap	210.62M
EPS	SEK-0.130 ( 2024-05-27 )
Next earnings date	( SEK-0.170 ) 2024-08-22
Last Dividend	SEK0 ( N/A )
Next Dividend	SEK0 ( N/A )
P/E	-2.48
ATR14	SEK0.00700 (0.40%)

Volume Correlation

Long: 0.01 (neutral)

Short: 0.67 (moderate)

Signal:(56.506) Neutral

Kancera AB (publ) Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Kancera AB (publ) Correlation - Currency/Commodity

-0.45
( neutral )

-0.05
( neutral )

0.00
( neutral )

-0.51
( weak negative )

-0.61
( weak negative )

Kancera AB (publ) Financials

Annual	2023
Revenue:	SEK1.04M
Gross Profit:	SEK-1.97M (-189.86 %)
EPS:	SEK-0.800

FY	2023
Revenue:	SEK1.04M
Gross Profit:	SEK-1.97M (-189.86 %)
EPS:	SEK-0.800

FY	2022
Revenue:	SEK753 000
Gross Profit:	SEK393 000 (52.19 %)
EPS:	SEK-0.880

Financial Reports:

No articles found.

Kancera AB (publ) Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Kancera AB (publ)

Kancera AB (Publ) develops drugs for inflammatory diseases and cancer in Sweden and internationally. The company is developing small molecule drug candidates KAND567, which is in phase IIa clinical trial for inflammatory heart disease following infarction, as well as KAND145, which is in phase I study in healthy subjects to document desired dose levels against cancer; and Phase IIa study for the treatment of ovarian cancer. It also develops HDAC for the treatment of nerve inflammation and pain; and ROR1 inhibitors for the treatment of solid tumors and blood cancers. Kancera AB (Publ) was founded in 2010 and is based in Solna, Sweden.